Naturally Splendid Responds to Health Canada’s Information Request Notice

Vancouver, British Columbia – TheNewswire – October 16, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) has responded through their joint venture Plasm Pharmaceutical (“Plasm”) to Health Canada’s Information Request Notice (“IRN”). The questions as posed by Health Canada are considered a formality as Plasm Pharmaceutical, continues to prepare for aContinue reading “Naturally Splendid Responds to Health Canada’s Information Request Notice”

Health Canada Requests Protocol Details of COVID-19 Phase 2 Clinical Trial

– TheNewswire – August 10, 2020 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) advises that subsequent to Heath Canada issuing a No Objection Letter, they have requested specific protocol details regarding the Clinical Trial Application for CavaltinibTM, the target drug of the proposed joint venture with Biologic Pharmaceutical Research, before the trial may commence.Continue reading “Health Canada Requests Protocol Details of COVID-19 Phase 2 Clinical Trial”

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

— Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory PhaseContinue reading “Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19”